Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7580955 | 1.00 | MEN1 (0.32) | MEN1ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL20014064 | 0.71 | MAPK1 (0.33) | LMNA | |
| SCHEMBL7099395 | 0.68 | LMNA (0.39) | MEN1ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL13946305 | 0.68 | LMNA (0.39) | MEN1ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL13809215 | 0.68 | LMNA (0.39) | MEN1ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL17893334 | 0.68 | LMNA (0.39) | MEN1ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL7103950 | 0.68 | LMNA (0.39) | MEN1ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL426068 | 0.68 | LMNA (0.39) | MEN1ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL16347736 | 0.67 | ALDH1A1 (0.47) | MEN1ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL5987624 | 0.67 | ALDH1A1 (0.47) | MEN1ALDH1A1LMNAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069362-A1 | Novel Spiro-benzo[c]chromene derivatives useful as modulators of the estrogen receptors | ZHANG XUQING | 2009-03-12 | — | — | US | claimed |
| US-7452914-B2 | Spiro-benzo[c]chromene derivatives useful as modulators of the estrogen receptors | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-18 | — | — | US | claimed |
| US-20080221125-A1 | NOVEL HETEROCYCLIC BENZO[C]CHROMENE DERIVATIVES USEFUL AS MODULATORS OF THE ESTROGEN RECEPTORS | ZHANG XUQING | 2008-09-11 | — | — | US | claimed |
| US-7399767-B2 | Heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-07-15 | — | — | US | claimed |
| US-7329654-B2 | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-12 | — | — | US | claimed |
| US-20060205741-A1 | Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-09-14 | — | — | US | claimed |
| EP-1467998-B1 | TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS | ORTHO MCNEIL PHARM INC (US) | 2006-03-29 | — | — | EP | claimed |
| US-20060020018-A1 | Novel spiro-benzo[c]chromene derivatives useful as modulators of the estrogen receptors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-01-26 | — | — | US | claimed |
| EP-1467998-A1 | TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2004-10-20 | — | — | EP | claimed |
| US-20030216463-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-11-20 | — | — | US | claimed |
| WO-2003053977-A1 | TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-07-03 | — | — | WO | claimed |
| US-9890233-B2 | Resist composition, method of forming resist pattern, and polymeric compound | TOKYO OHKA KOGYO CO., LTD. (JP) | 2018-02-13 | — | — | US | disclosed |
| US-20150198880-A1 | RESIST COMPOSITION, METHOD OF FORMING RESIST PATTERN, AND POLYMERIC COMPOUND | TOKYO OHKA KOGYO CO., LTD. (JP) | 2015-07-16 | — | — | US | disclosed |
| US-8580478-B2 | Latent acids and their use | BASF SE (DE) | 2013-11-12 | — | — | US | disclosed |
| US-8580478-B2 | Latent acids and their use | BASF SE (DE) | 2013-11-12 | — | — | US | disclosed |
| US-7105679-B2 | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | KANOJIA RAMESH M | 2006-09-12 | — | — | US | disclosed |
| EP-1467998-B1 | TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS | ORTHO MCNEIL PHARM INC (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20060020018-A1 | Novel spiro-benzo[c]chromene derivatives useful as modulators of the estrogen receptors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-01-26 | — | — | US | disclosed |
| US-20040259915-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | KANOJIA RAMESH M (US) | 2004-12-23 | — | — | US | disclosed |
| US-20030216463-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205741-A1 | Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors | GPER1, ESR1, ESR2 | MEN1 1519/4885ALDH1A1 2052/4885LMNA 1400/4885 |
| US-20060020018-A1 | Novel spiro-benzo[c]chromene derivatives useful as modulators of the estrogen receptors | ESR2, ESR1, ESRRA | MEN1 1829/4885ALDH1A1 1463/4885LMNA 1358/4885 |
| US-20040259915-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | GPER1, ESR2, FSHR | MEN1 3109/4885ALDH1A1 2801/4885LMNA 3427/4885 |
| US-20080221125-A1 | NOVEL HETEROCYCLIC BENZO[C]CHROMENE DERIVATIVES USEFUL AS MODULATORS OF THE ESTROGEN RECEPTORS | GPER1, ESR1, ESR2 | MEN1 1519/4885ALDH1A1 2052/4885LMNA 1400/4885 |
| US-20030216463-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | GPER1, ESR2, FSHR | MEN1 3109/4885ALDH1A1 2801/4885LMNA 3427/4885 |
| US-20090069362-A1 | Novel Spiro-benzo[c]chromene derivatives useful as modulators of the estrogen receptors | ESR2, ESR1, ESRRA | MEN1 1829/4885ALDH1A1 1463/4885LMNA 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.